VIFOR-PHARMA
21.12.2021 07:02:12 CET | Business Wire | Press release
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.
85% of the more than 1,000 patients with either high risk of hyperkalemia or active hyperkalemia were able to be optimized to guideline recommended, life-saving RAASi treatment, including mineralocorticoid receptor antagonists, with Veltassa® during the run-in phase of the study. This shows that the gap between guideline recommendations and real-world practice regarding the use of RAASi can be addressed with Veltassa® . Veltassa® was generally well tolerated and without unexpected safety findings. Vifor Pharma expects the key trial results to be presented at a major cardiology conference in H1 2022.
“We are delighted and very encouraged about the positive read-out from the DIAMOND trial for the heart failure patient community,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “RAASi therapy saves lives and delays disease progression, but unfortunately many patients with heart failure are insufficiently treated due to risk of hyperkalemia. Hyperkalemia is a serious condition associated with life-threatening consequences. These data support an effective management of chronic hyperkalemia in heart failure patients on optimal RAASi therapy with Veltassa® . We look forward to presenting the detailed data to the scientific community in the first half of 2022.”
“This trial makes a significant contribution to the growing body of evidence showing the importance to use Veltassa® to enable RAASi and ensures optimal treatment in a high-risk population”, commented Prof. Javed Butler, Principal Investigator for the DIAMOND study. “The totality of evidence from the trials with patiromer suggests the treatment to control serum potassium and preventing hyperkalemia in heart failure patients aiding longer term optimal medical therapy.”
Vifor Pharma continues to support several data generation programs with the ongoing phase-IV PLATINUM study and the CARE-HK in HF global registry to drive evidence-based care using Veltassa® in chronic kidney disease and heart failure patients.
About the DIAMOND trial
This global, multicenter, double-blind, placebo controlled study was designed to evaluate the potential role of Veltassa®
in enabling patients with, or at high risk of, hyperkalemia to remain on RAASi therapy. On recommendation of the independent study Executive Committee and due to COVID-19 impact on recruitment, the primary endpoint has been changed in June 2021 to investigate the role of Veltassa®
in controlling serum potassium, preventing hyperkalemia and maintain RAASi use in heart failure patients.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Royal Moroccan Football Federation Acknowledges Decision Rendered by the CAF Appeals Committee18.3.2026 18:49:00 CET | Press release
The Royal Moroccan Football Federation (FRMF) wishes to reiterate that its appeal was never aimed at contesting the sporting merit or performance of the teams involved in this tournament, but solely to ensure the proper enforcement of competition regulations. The federation reaffirms its commitment to respecting the regulations, ensuring the clarity of the competitive framework and maintaining the stability of African football competitions. The Federation also wishes to commend all the nations that participated in this year’s edition of the Africa Cup of Nations (AFCON), which served as a significant moment for African football. The FRMF will issue a more comprehensive official statement in the coming days after a scheduled meeting of its governing bodies. Source: AETOSWire View source version on businesswire.com: https://www.businesswire.com/news/home/20260318763307/en/
SIMCON Unveils World’s First Large Engineering Model for Plastic Injection Moulding18.3.2026 18:05:00 CET | Press release
SIMCON today announced the launch of the Cadmould AI Solver, the world’s first Large Engineering Model for injection moulding. Co-developed with Emmi AI, the new transformer-based architecture delivers simulation results up to 1000 times faster than traditional numerical solvers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318680159/en/ SIMCON’s new Cadmould AI Solver delivers injection molding simulation results in seconds. By removing lengthy computation times, the tool enables engineers to dynamically explore thousands of design and process variations in a single day. Historically, lengthy computation times have acted as a bottleneck, limiting the number of design variations engineers can practically explore during the development process. The Cadmould AI Solver shatters this barrier by providing engineers with instant feedback on filling pattern, pressure, and temperature in seconds. What once required hours per si
Boomi, a 12X Leader, Positioned Highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service18.3.2026 16:30:00 CET | Press release
Boomi™, the data activation company, today announced it has been recognized as a Leader and positioned highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS). This marks the 12th consecutive time Boomi has been named a Leader– the longest recognized vendor in the report’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318987091/en/ Boomi, a 12X Leader, Positioned Highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service Boomi attributes its continued industry recognition to its unwavering commitment to innovation, customer success, and ecosystem growth. Over the past year, Boomi has accelerated its investments in integration and automation, APIM, agent management, and data management to help enterprises transform fragmented systems and data into orchestrated processes and governed agentic workflows. Recent i
Laserfiche Announces 2026 Run Smarter® Award Winners18.3.2026 15:17:00 CET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — today announced the winners of the 2026 Laserfiche Run Smarter® Awards. These awards celebrate the visionaries and trailblazers who are redefining the possible, using Laserfiche to break down operational silos and catalyze a new era of enterprise-wide productivity. From a large city reimagining criminal justice to a financial services firm’s innovative use of AI for smarter service delivery: The winners enhance productivity, reimagine processes and improve lives with Laserfiche technology. “The true power of Laserfiche has always been in how it unlocks value — whether that is through delivering actionable intelligence, cost savings, or reclaimed time to put toward innovation,” said Karl Chan, CEO of Laserfiche. “This year’s honorees are at the forefront of information management, with many of them leveraging cloud and AI technology to modernize processes and achieve business transformation.” Congratulations to t
I-Pulse Acquires CSI Technologies to Strengthen U.S. High-Energy Capacitor Manufacturing Capabilities18.3.2026 14:30:00 CET | Press release
I-Pulse Acquires California Capacitor Specialist CSI Technologies to Advance Disruptive Pulsed Power ApplicationsCSI Acquisition Secures Strategic Technologies Central to I-Pulse’s Pulsed Power Roadmap Co-Founder, Chairman, and CEO, Robert Friedland, and Co-Founder and Chief Technology Officer, Laurent Frescaline, of I-Pulse, the world leader in high pulsed power technologies, are pleased to announce the acquisition of CSI Technologies, Inc., the California-based manufacturer of high-energy, high-voltage capacitors serving industrial, medical, and defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318099794/en/ The strategic acquisition enhances I-Pulse’s pulsed power development and U.S. manufacturing capabilities, particularly in mining, geothermal energy, mineral exploration, and water resource applications. By integrating CSI Technologies’ proven capacitor design and production expertise, I-Pulse str
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom